Ponatinib has been approved for CML and Ph-positive (Ph+) acute lymphoblastic leukemia (ALL) resistant or intolerant to prior TKI therapy or for patients carrying the point mutation threonine to isoleucine at codon 315 (T315I) in BCR/ABL1 kinase domain, a frequent somatic mutation associated with resistance to first- and second-generation TKIs [100]. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.